Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.
- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.
- Veracyte will combine these assets with its multi-omics testing and machine learning capabilities to create a Veracyte Biopharma Atlas reference database of genomic and immunomic biomarkers.
- “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients tumor samples and data from innovative cancer therapies.
- Ultimately, we believe this tool may help our biopharmaceutical partners accelerate development of new, precision-medicine therapies that improve outcomes for patients with cancer.”